» Articles » PMID: 34466494

Reduced Levels of MiR-28 and MiR-200a Act As Predictor Biomarkers of Aggressive Clinicopathological Characteristics in Gastric Cancer Patients

Overview
Journal Galen Med J
Specialty General Medicine
Date 2021 Sep 1
PMID 34466494
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: MicroRNAs (miRNAs) play critical roles in different pathological processes including cancer development and progression. To find novel molecular diagnostic and prognostic markers and promising therapeutic tools for gastric cancer (GC), we aimed to investigate the relationship of the expression levels of miR-28-5p or miR-200a-3p with the clinicopathological criteria and to explore their impacts on the progression of human GC.

Materials And Methods: Quantitative RT-PCR was performed to analyze miR-28 and miR-200a expression in 60 GC and 60 non-GC tissue samples.

Result: Our results revealed that the expressions of miR-200a and miR-28 were significantly downregulated in GC in comparison with non- GC tissues. Tumors with low miR-28 expression had larger tumor size, more advanced histological grade, and a higher incidence of lymph node and distal metastasis than the tumors with high miR-28 expressions. Furthermore, receiver operating characteristic (ROC) analyses demonstrate that the expression of miR-28 is a predictive biomarker allows predicting the histological grade, tumor size, and occurrence of nodal and distal metastases. We also found a significant inverse association between miR-200a expression and the rate of lymph node metastasis (p = 0.010, r = -0.334).

Conclusion: Our findings suggest that the miR-28 and miR-200a have tumor-suppressor functions and may be considered as potential biomarkers for gastric cancer diagnosis and prognosis.

Citing Articles

The interplay between microRNAs and Nrf2 signaling in human cancers.

Panahizadeh R, Vatankhah M, Safari A, Danesh H, Nazmi N, Gholizadeh P Cancer Cell Int. 2024; 24(1):234.

PMID: 38970040 PMC: 11225148. DOI: 10.1186/s12935-024-03430-1.


An update of Nrf2 activators and inhibitors in cancer prevention/promotion.

Pouremamali F, Pouremamali A, Dadashpour M, Soozangar N, Jeddi F Cell Commun Signal. 2022; 20(1):100.

PMID: 35773670 PMC: 9245222. DOI: 10.1186/s12964-022-00906-3.


Development of a Magnetic Nanostructure for Co-delivery of Metformin and Silibinin on Growth of Lung Cancer Cells: Possible Action Through Leptin Gene and its Receptor Regulation.

Salmani Javan E, Lotfi F, Jafari-Gharabaghlou D, Mousazadeh H, Dadashpour M, Zarghami N Asian Pac J Cancer Prev. 2022; 23(2):519-527.

PMID: 35225464 PMC: 9272620. DOI: 10.31557/APJCP.2022.23.2.519.


miR-140 and miR-196a as Potential Biomarkers in Breast Cancer Patients.

Shahabi A, Naghili B, Ansarin K, Montazeri V, Zarghami N Asian Pac J Cancer Prev. 2020; 21(7):1913-1918.

PMID: 32711415 PMC: 7573432. DOI: 10.31557/APJCP.2020.21.7.1913.

References
1.
Shrestha S, Hsu S, Huang W, Huang H, Chen W, Weng S . A systematic review of microRNA expression profiling studies in human gastric cancer. Cancer Med. 2014; 3(4):878-88. PMC: 4303155. DOI: 10.1002/cam4.246. View

2.
Zhou S, Hu Z, Zhou Z, Dai Z, Wang Z, Cao Y . miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology. 2016; 63(5):1560-75. DOI: 10.1002/hep.28445. View

3.
Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

4.
Yu X, Ma C, Fu L, Dong J, Ying J . MicroRNA-139 inhibits the proliferation, migration and invasion of gastric cancer cells by directly targeting ρ-associated protein kinase 1. Oncol Lett. 2018; 15(4):5977-5982. PMC: 5840708. DOI: 10.3892/ol.2018.8038. View

5.
Melo S, Esteller M . Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 2010; 585(13):2087-99. DOI: 10.1016/j.febslet.2010.08.009. View